Agenda
� 3:00-3:30 PM Networking & Registration
� 3:30-5:00 PM Experts Panel
� 5:00-6:30 PM Networking Reception

You often have brilliant ideas about new or improved products, but ultimately it is the customer who decides whether your product is valuable or not. Planning for commercial success starts at the research stage and parallels the entire R&D; process.

During this session, experts will discuss how to decide which product to commercialize, when to do a second generation, exit strategies VCs are looking for, what strategy to adopt as you are going through the development process...

The roundtable discussion format is interactive and informal and intended to be a conversation more than a presentation. So bring your questions with you!


Moderator
Scott M. Iyama, Corporate Lawyer, Member of the Emerging Companies Group, Orrick, Herrington & Sutcliffe LLP ~ Click for Bio


Panelists
Brian Pelkowski, Strategy Marketing Manager, Immunology, Genentech Inc. ~ Click for Bio
Sean McCarthy, D.Phil., MBA, Principal, Pappas Ventures ~ Click for Bio
Martin Babler, former Vice President of Immunology Sales and Marketing at Genentech, Inc. ~ Click for Bio
Jaisim Shah, Senior Vice President, Marketing and Business Affairs, PDL BioPharma ~ Click for Bio


Cost & Registration
� Regular Price ~ $25
� Partners' Network ~ $15
� SJBC members ~ Free
� Door Registration: add $5




Venue
The San Jose BioCenter
5941 Optical Court
San Jose, CA 95138
Click here for Venue Directions


Moderator & Panelists' Bios

Scott M. Iyama, Corporate Lawyer, Member of the Emerging Companies Group, Orrick, Herrington & Sutcliffe LLP
Scott Iyama, a corporate lawyer in Orrick's Silicon Valley office, is a member of the Emerging Companies Group, which advises emerging companies and venture capital firms. Mr. Iyama's practice focuses on the representation of emerging growth life science and high tech companies, as well as public offerings, private venture financings, and technology transactions. Some of Mr. Iyama�s clients include: AcroMetrix (funded by Telegraph Hill Partners), Facebook (funded by Accel Partners, Greylock, Meritech and Peter Thiel), Greenplum (funded by Sierra, Dawntreader, EDF, Hudson & Mission), Laserscope (acquired by American Medical Systems Holdings), Meebo (funded by Sequoia Capital), Medsphere (funded by Thomas Weisel Venture Partners, Azure Capital, and Wasatch Venture Fund), Micrus Endovascular (NASDAQ: MEND), Sharpcast (funded by Sigma, Selby and Draper Fisher Jurvetson), SquareOne (privately funded), Vendavo (funded by Sigma Partners, Doll Capital Management, InterWest Partners, and others), W5 Networks (funded by Thomas Weisel Venture Partners and U.S. Venture Partners)... Mr. Iyama has also represented Benchmark Capital, De Novo Ventures, Kleiner Perkins Caufield & Byers, Maveron, Montreux Equity Partners, Telegraph Hill Partners and other venture funds in various investments. Mr. Iyama frequently lectures on topics related to emerging growth companies at various forums including Stanford Law School and Stanford University. Prior to receiving his J.D. from Stanford Law School, Mr. Iyama earned a B.S. in Biochemistry and Cell Biology and a M.S. in Biology from the University of California, San Diego. While at the University of California, San Diego, Mr. Iyama performed extensive biochemical research focusing on the general mechanisms governing the initiation of transcription by RNA Polymerase II as well as co-creating the Drosophila Core Promoter Database.
Brian Pelkowski, Strategy Marketing Manager, Immunology, Genentech Inc.
Brian Pelkowski has been at Genentech for the past four years. He moved into his current role as Group Product Manager, Strategy for Rituxan Immunology at the start of this year. Prior to this transition, Brian spent two years leading the Market Planning group responsible for assessing the commercial value and recommending the commercial strategy for internal and external oncology development opportunities. Additionally, Brian�s group provided the Rituxan Hem/Onc team with recommendations and analysis on the hematology marketplace and the opportunities for sustained growth. Before joining Genentech, Brian spent over five years as a consultant to pharmaceutical and biotechnology companies working on valuations, mergers and asset allocation projects. Brian received an MBA from the Kellogg School of Management.
Sean McCarthy, D.Phil., MBA, Principal, Pappas Ventures
Sean has ten years of operating experience in the biotechnology industry in business development, program management and research management. He has held positions at Millennium Pharmaceuticals and SGX Pharmaceuticals, an oncology focused biotechnology company located in San Diego, where he served as Vice President of Business Development. Under his leadership SGX entered into a wide range of strategic partnerships with major pharmaceutical companies including Eli Lilly, Roche and Novartis, with whom a $515M oncology alliance was forged in March 2006 to develop novel therapies for chronic myelogenous leukemia. Prior to SGX, Sean was responsible for research into gene discovery and for management of several drug discovery programs at Millennium. His discovery team invented novel genomic techniques for the identification of therapeutic proteins and played a central role in a major alliance with Eli Lilly. He is the author of 17 peer reviewed scientific publications and an inventor on 29 issued patents and filed patent applications. Sean joined Pappas Ventures in August 2006 and is a board observer at CoLucid Pharmaceuticals.
Martin Babler, former Vice President of Immunology Sales and Marketing at Genentech, Inc.
Martin Babler was until recently VP of Immunology Sales and Marketing at Genentech with responsibility for Xolair, Rituxan Immunology and the late stage Immunology pipeline. Prior to this, Martin was Senior Director and head of Commercial Development in charge of marketing and strategic input for all products in Genentech's pipeline across the different therapeutic areas. His team was focused on creating high value assets in close collaboration with Research and Development and introduced several new tools and systems to the organization that help optimize product launches. Martin joined Genentech several years ago as Director of Marketing in the Cardiovascular Franchise.
Prior to joining Genentech, Martin held various roles of increasing responsibility in sales, sales management, marketing and business development on a global as well as affiliate level with Eli Lilly and Company. Martin Babler holds a degree in Pharmacy/Pharmacology from the ETH in Zurich, Switzerland and has attended the Executive Development Program at Kellogg Graduate School of Management.
Jaisim Shah, Senior Vice President, Marketing and Business Affairs, PDL BioPharma
Currently Jaisim Shah serves as the Senior Vice President, Marketing & Business Affairs at PDL BioPharma, where he has worked for the last six years. His previous position at PDL was VP Marketing & Medical Affairs. Jaisim came to PDL with U.S. and worldwide pharmaceutical experience. Prior to joining the company, he was associated with Bristol-Myers Squibb, where from 1997 he held various management level positions including Vice President of Marketing for the U.S. infectious disease business, and Vice President of Global Marketing for the neuroscience and urology franchises. He began his pharmaceutical career in 1986 as a U.S. sales representative for the Upjohn Company, and subsequently conducted market planning for the Chugai-Upjohn biotechnology joint venture. Jaisim joined Roche Laboratories in 1991 as Product Director for biotechnology oncology products for the U.S. market, and then became Global Business Leader for oncology and virology at Roche�s world headquarters in Basel, Switzerland in 1993. He has extensive experience working on blockbuster brands prior to and through launch. He holds Masters degree in Economics and Business.